In the News July 17, 2019

The Pink Sheet | Comparative Confusion: What Does FDA Intend for Opioid Comparative Efficacy Data?

Marc Scheineson comments on the U.S. Food and Drug Administration’s recent draft guidance on the benefit and risk assessment for opioids.
Media Contact
Alex Wolfe
Communications Director

This website uses cookies to improve functionality and performance. For more information, see our Privacy Statement. Additional details for California consumers can be found here.